Skip to main content
Log in

The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma

  • Image of the month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ell PJ, Gambhir SS. Nuclear medicine in clinical diagnoses and treatment. 3rd ed. New York: Churchill Livingstone; 2004

  2. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7

    Article  PubMed  CAS  Google Scholar 

  3. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-DPhe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8

    Article  PubMed  Google Scholar 

  4. Lewington V. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003;10(4):497–501

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zarni Win.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Win, Z., Rahman, L., Murrell, J. et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 33, 506 (2006). https://doi.org/10.1007/s00259-005-0035-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0035-9

Keywords

Navigation